Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Trial of Oral Ozanimod in Relapsing Multiple Sclerosis
2015-002500-91Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ozanimod in multiple sclerosis (MS), sponsored by Celgene Corporation. Primary endpoints: Long-term safety and tolerability of ozanimod (RPC1063) and Long-term efficacy of ozanimod (RPC1063). Started Aug 2015; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-002500-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002500-91.